Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Moderna, Inc. Common Stock (MRNA)

Biological Products, (no Disgnostic Substances)

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

200 TECHNOLOGY SQUARE
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/07/2018

Market Cap

33,396,324,480

Shares Outstanding

381,280,000

Weighted SO

381,283,996

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

CVAC --.--%

NVAX --.--%

CWBR --.--%

RETA --.--%

OCEA --.--%

ENVB --.--%

HEPA --.--%

ELEV --.--%

Beta

1.6620

Last Div

0.0000

Range

62.55-170.47

Chg

0.2600

Avg Vol

4195283

Mkt Cap

33396324480

Exch

NASDAQ

Country

US

Phone

617 714 6500

DCF Diff

163.9712

DCF

-76.6812

Div Yield

0.0000

P/S

6.6105

EV Multiple

-8.0168

P/FV

2.8485

Div Yield %

0.0000

P/E

-5.6864

PEG

-0.1583

Payout

0.0000

Current Ratio

4.0884

Quick Ratio

3.9196

Cash Ratio

1.0487

DSO

30.5612

DIO

42.1154

Op Cycle

72.6765

DPO

29.4491

CCC

43.2274

Gross Margin

0.3155

Op Margin

-0.9175

Pretax Margin

-0.8575

Net Margin

-1.1613

Eff Tax Rate

-0.3543

ROA

-0.3742

ROE

-0.4527

ROCE

-0.3481

NI/EBT

1.3543

EBT/EBIT

0.9346

EBIT/Rev

-0.9175

Debt Ratio

0.0809

D/E

0.1084

LT Debt/Cap

0.0960

Total Debt/Cap

0.0978

Int Coverage

-210.6818

CF/Debt

-2.5540

Equity Multi

1.3388

Rec Turnover

11.9433

Pay Turnover

12.3943

Inv Turnover

8.6667

FA Turnover

1.7004

Asset Turnover

0.3222

OCF/Share

-8.4401

FCF/Share

-10.3620

Cash/Share

22.1042

OCF/Sales

-0.6415

FCF/OCF

1.2277

CF Coverage

-2.5540

ST Coverage

-129.6400

CapEx Coverage

-4.3916

Div&CapEx Cov

-4.3916

P/BV

2.8485

P/B

2.8485

P/S

6.6105

P/E

-5.6864

P/FCF

-8.3931

P/OCF

-10.2937

P/CF

-10.2937

PEG

-0.1583

P/S

6.6105

EV Multiple

-8.0168

P/FV

2.8485

DPS

0.0000

Latest Headlines (EST)

Benzinga Apr 11, 20:36 Stocks Notch Best Week In Years As Dip Buying On Tariff Crisis Gathers Momentum The Motley Fool Mar 19, 22:10 2 No-Brainer Biotech Stocks to Buy Right Now The Motley Fool Feb 09, 16:15 2 Biotech Stocks to Buy Hand Over Fist in February The Motley Fool Jan 25, 20:11 Why Moderna Stock Jumped Over 20% This Week GlobeNewswire Inc. Nov 19, 01:23 SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi GlobeNewswire Inc. Nov 07, 02:13 DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi GlobeNewswire Inc. Oct 31, 01:09 INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi The Motley Fool Oct 19, 22:15 How Bad Is This News for Novavax? GlobeNewswire Inc. Oct 19, 17:22 ???????? RLF ?? Metagenomi, Inc. ?????????????????????? – MGX GlobeNewswire Inc. Oct 18, 21:56 RLF, NATIONAL TRIAL COUNSEL, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGX GlobeNewswire Inc. Oct 16, 22:39 MGX Stock News: Robbins LLP Reminds Investors with Large Losses of the Class Action Lawsuit Against Metagenomi Inc. GlobeNewswire Inc. Oct 13, 17:19 ROSEN, A TOP RANKED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGX The Motley Fool Oct 12, 12:30 2 Biotech Stocks That Are Screaming Buys This Month GlobeNewswire Inc. Oct 11, 00:44 ROSEN, A LEADING LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGX GlobeNewswire Inc. Oct 06, 15:13 MRNA DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA GlobeNewswire Inc. Oct 04, 21:27 ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGX GlobeNewswire Inc. Sep 30, 00:30 Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO) GlobeNewswire Inc. Sep 29, 19:12 ROSEN, A TOP RANKED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGX GlobeNewswire Inc. Sep 27, 22:11 MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit with the Schall Law Firm GlobeNewswire Inc. Sep 27, 01:14 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Metagenomi, Inc. Stock and Sets a Lead Plaintiff Deadline of November 25, 2024

Revenue Product Segmentation